Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak오미크론 발병 이전 이집트에서 가장 흔한 SARS-CoV-2 변종에 대한 다양한 유형의 백신에 대한 체액성 면역 유도Article Published on 2022-07-302022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Ad26 Ad26.COV2.S AstraZeneca B.1 BBIBP-CorV BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 collected COVID-19 COVID-19 pandemic Delta Diversity effective Effectiveness elicited Humoral immunity induced janssen lead microneutralization Microneutralization assay Neutralizing activity Neutralizing antibodies Neutralizing antibody response neutralizing antibody responses new SARS-CoV-2 omicron outbreak participant Pfizer-BioNTech SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 vaccine SARS-CoV-2 variants Sinopharm the SARS-CoV-2 Vaccine vaccine effectiveness vaccine-induced antibodies vaccine-induced antibody variant variants variants of SARS-CoV-2 was determined while [DOI] 10.1016/j.vaccine.2022.05.086 PMC 바로가기 [Article Type] Article
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccinesCOVID-19 mRNA 백신에 의해 유도된 항체에 의한 SARS-CoV-2 변이체의 차등 중화 및 억제Article Published on 2022-07-272022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha antibody Beta booster collected coronavirus COVID-19 mRNA vaccine COVID-19 pandemic Delta disease dose effective elicited Epsilon Eta Evolution exacerbated Factor Gamma International Iota Lambda Lineage moderate mRNA mRNA vaccine National neutralization Neutralizing activity omicron Omicron variant reductions in Replication respiratory risk SARS-CoV-2 SARS-CoV-2 variant sera severe acute respiratory syndrome Coronavirus vaccination Vaccine vaccine-induced antibodies variant variants VoC VOCs VOIs Zeta [DOI] 10.1038/s41467-022-31929-6 PMC 바로가기 [Article Type] Article
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults이종 프라임-부스트 백신 접종 후 BNT162b2 부스터는 젊은 성인에서 SARS-CoV-2 Omicron BA.1에 대한 강력한 중화 항체 및 T 세포 반응성을 유도합니다Article Published on 2022-07-252022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Adults analysed Antibody titer Antibody titers B.1 B.1.1.529.1 BA.1 BNT162b2 booster Cell cellular immunity ChAdOx1 ChAdOx1 nCoV-19 Cohort Course COVID-19 defined Delta dominant Effect effective elicited Epitopes Heterologous heterologous prime-boost humoral humoral and cellular immunity Humoral immunity immune immune protection immune responses Immunity individual induce initial interval maturation memory T memory T cell memory T cells nCoV neutralization titer neutralization titers neutralized Neutralizing activity neutralizing antibody omicron performed reactivity residual responses against resulting SARS-CoV-2 SARS-COV-2 infection spike epitope spike epitopes subsequent symptomatic SARS-CoV-2 infection T cell T cells the early SARS-CoV-2 vaccination vaccination interval. Vaccinations variant variants variants of concern VOCs [DOI] 10.3389/fimmu.2022.882918 PMC 바로가기 [Article Type] Article
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeysArticle Published on 2022-07-252022-10-05 Journal: Nature Microbiology [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] class Combination Complete complex Cryo-electron microscopy Donor epitope Fab Human monoclonal antibody identify in vitro less mAb monoclonal antibody Mutation neutralization neutralize Neutralizing activity omicron other variant Prophylactic reported SARS-CoV-2 SARS-CoV-2 mutant sequence spike epitope tested therapeutic therapy Transmission vaccine-mediated immunity variant [DOI] 10.1038/s41564-022-01198-6 [Article Type] Article
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses증례 보고: 백신 접종 반응이 없는 다발성 경화증 환자에서 SARS-CoV-2 감염의 변종 특이적 노출 전 예방Case Reports Published on 2022-07-252022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-CD20 treatment antibody cocktail approved Asymptomatic Case report Case series case sery Casirivimab cilgavimab conducted coronavirus coronavirus disease coronavirus disease (COVID-19) COVID-19 infection develop dose European Evidence evidence of FIVE humoral Imdevimab immunomodulatory Immunotherapy impair incidence Infection Initially monoclonal monoclonal antibody multiple sclerosis Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody offered omicron Omicron variant one patient pandemic Patient patients positive RT-PCR predominant prophylactic treatment Prophylaxis receptor reduced respiratory respiratory tract infection response retained Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pandemic SARS-CoV-2-neutralizing antibodies SARS-CoV-2-neutralizing antibody SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severe adverse event severe adverse events Sotrovimab specific antibodies sphingosine sphingosine-1-phosphate sphingosine-1-receptor modulators (S1PR) sustained Symptom T-cell T-cells the patient the SARS-CoV-2 Tixagevimab Treatment union upper respiratory tract upper respiratory tract infection vaccination vaccination response variant were recorded [DOI] 10.3389/fimmu.2022.897748 PMC 바로가기 [Article Type] Case Reports
Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate백시니아 바이러스 기반 중증급성호흡기증후군 코로나바이러스 2 백신 후보의 면역원성Article Published on 2022-07-222022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Antibody Response B.1.1.529 B.1.351 B.1.617.2 coronavirus COVID-19 COVID-19 pandemic develop Express immunogenicity inactivated mice mRNA Neutralizing activity recombinant spike proteins respiratory robust SARS-CoV-2 SARS-CoV-2 particles SARS-CoV-2 spike SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2 vaccines sera severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spike protein Spike proteins Support T-cell Response the SARS-CoV-2 Vaccine vaccine candidate vaccinia virus variants variants of concern vector Viral viral spike protein viral vectors VOCs was used Wuhan [DOI] 10.3389/fimmu.2022.911164 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 OutbreakCOVID-19 발병 동안 진행된 HIV 감염자의 SARS-CoV-2 특이적 면역 반응 및 염증 프로필Article Published on 2022-07-202022-09-12 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] advanced HIV infection age Analysis analyzed Antibody titer CD4 Comorbidity Comparisons COVID-19 Duration of infection effective ELISA assay ELISpot assay evaluate evaluated expand HIV HIV infection HIV-negative humoral IL-1β IL-6 IL-8 Immunity immunological induce Infection Inflammation Inflammatory Inflammatory marker inflammatory state IQR Kruskal-Wallis test mandatory Mann-Whitney median neutralize Neutralizing activity occurred outbreak outcomes overall mortality Patient patients with HIV patients without COVID-19 persistence Person positive profile quantified response SARS-CoV-2 severity of COVID-19 Specific Specific T-cell response tested TNF-α TNFα vaccination were used [DOI] 10.3390/v14071575 PMC 바로가기 [Article Type] Article
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantSARS-CoV-2 오미크론 변이체에 대한 백신 강화 중화 항체의 급격한 감소Clinical Trial Published on 2022-07-192022-09-11 Journal: Cell Reports Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus BA.2.12.1 BA.4/BA.5 boost booster Combination conducted coronavirus COVID-19 D614G variant exhibit generate Heterologous homologous implication magnitude mRNA mRNA vaccine neutralization titer neutralization titers Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody omicron Omicron variant PROTECT protective immunity Rapid recombinant adenovirus recombinant adenovirus vaccine reduced respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus sublineage. susceptibility Trial Vaccines variant variants of SARS-CoV-2 [DOI] 10.1016/j.xcrm.2022.100679 PMC 바로가기 [Article Type] Clinical Trial
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection AlonePre-Omicron 백신의 획기적인 감염은 단독 감염에 비해 SARS-CoV-2 Omicron BA.1에 대해 우수한 교차 중화를 유도합니다Article Published on 2022-07-122022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] antibody antibody levels Antibody Response Antibody responses B.1 boost Breakthrough infection comparable convalescent convalescent sera convalescent serum correlated COVID-19 patient cross-neutralization cross-neutralizing antibodies cross-neutralizing antibody Delta disease elicited evade form Gamma had no higher affinity highlight Immunity individuals induce infecting Infection Live virus Mild moderate disease N-terminal domain neutralization neutralize Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody neutralizing capacity NTD nucleocapsid omicron Omicron BA.1 Patient patients with moderate Protein Proteins raise RBD Receptor-binding domain remained retained SARS-CoV-2 SARS-CoV-2 variants sera spike Spike protein Spike proteins strain Strains Superior the disease the RBD the receptor-binding domain the Spike the spike protein Transmissibility vaccination Vaccine Variability variant variants variants of concern variants of concern (VOCs) virus-induced antibodies VoC VOCs [DOI] 10.3390/ijms23147675 PMC 바로가기 [Article Type] Article
Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study한국 성인에서 Ad26.COV2.S의 면역원성과 반응성: 전향적 코호트 연구Article Published on 2022-07-112022-09-11 Journal: Journal of Korean medical science [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Adenovirus Adenovirus Vector Adverse adverse event adverse events AEs anti-S IgG Anti-spike baseline cellular immunity conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 decrease Delta Dilution enrolled enzyme enzyme-linked immunospot assay evaluated fatigue Fever followed by geometric mean geometric mean titers GMT GMTs GRADE Humoral immunity IgG antibody immunogenic immunogenicity injection site pain interferon interferon-γ Korean mononuclear cell MOST myalgia NAb titer Neutralizing Neutralizing activity neutralizing antibody responses omicron Omicron variant Omicron variants outcome pandemic participant Peripheral blood Prospective prospective cohort study resolved respiratory Safe SARS-CoV-2 serious AEs severe acute respiratory syndrome Coronavirus Single-dose South Korea T-cell immunity T-cell Response T-cell responses the median U/mL university hospital vaccination Vaccines variant variants Viral Viral variants waning immunity wild-type WT SARS-CoV-2 [DOI] 10.3346/jkms.2022.37.e210 PMC 바로가기 [Article Type] Article